NCT06327178View on ClinicalTrials.gov

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Trial Locations (1)

510515

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER